Genprex, Inc. announced the completion of Phase 1 of its Acclaim-3 clinical trial for Reqorsa Gene Therapy, with a recommended dose of 0.12 mg/kg approved for the Phase 2 expansion, which will enroll about 50 patients across 10 to 15 U.S. sites.